{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:04:16Z","timestamp":1793419456261,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.lfs.2020.118907","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:06:12Z","timestamp":1610305572000},"page":"118907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["The effects of drug transporters on the efficacy of methotrexate in the treatment of rheumatoid arthritis"],"prefix":"10.1016","volume":"268","author":[{"given":"Jinzhang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.118907_bb0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/kex036","article-title":"Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis","volume":"57","author":"Takase-Minegishi","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lfs.2020.118907_bb0010","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0015","first-page":"1631","article-title":"Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study","volume":"29","author":"Aletaha","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0020","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/ard.61.12.1055","article-title":"Ten year outcome in a cohort of patients with early rheumatoid arthritis health status, disease process, and damage","volume":"61","author":"Lindqvist","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118907_bb0025","first-page":"S40","article-title":"Methotrexate transport mechanisms: the basis for targeted drug delivery and \u00df-folate-receptor-specific treatment","volume":"28","author":"Fiehn","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0030","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4161\/cbt.22020","article-title":"The human proton-coupled folate transporter: biology and therapeutic applications to cancer","volume":"13","author":"Desmoulin","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lfs.2020.118907_bb0035","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.biopha.2006.09.007","article-title":"The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics","volume":"60","author":"Stamp","year":"2006","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2020.118907_bb0040","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3899\/jrheum.130066","article-title":"Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue","volume":"40","author":"Stamp","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0045","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2020.118907_bb0055","doi-asserted-by":"crossref","first-page":"238035","DOI":"10.1155\/2013\/238035","article-title":"Combination with methotrexate and cyclophosphamide attenuated maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo","volume":"2013","author":"Yu","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.lfs.2020.118907_bb0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10067-015-2861-x","article-title":"Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint","volume":"34","author":"Witte","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00296-016-3447-x","article-title":"Inadequate response or intolerability to oral methotrexate: is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics","volume":"36","author":"Yadlapati","year":"2016","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.lfs.2020.118907_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010227.pub2","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis","author":"Hazlewood","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2020.118907_bb0075","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/ard.2009.127332","article-title":"Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gorter","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118907_bb0080","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rdc.2018.06.008","article-title":"Renal manifestations of rheumatoid arthritis","volume":"44","author":"Kapoor","year":"2018","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.lfs.2020.118907_bb0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rdc.2017.09.005","article-title":"Gastrointestinal and hepatic disease in rheumatoid arthritis","volume":"44","author":"Craig","year":"2018","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.lfs.2020.118907_bb0090","first-page":"563","article-title":"Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate","volume":"32","author":"Pichlmeier","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0095","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.2174\/1381612823666170601105439","article-title":"Methotrexate in the treatment of psoriasis and rheumatoid arthritis: mechanistic insights, current issues and novel delivery approaches","volume":"23","author":"Rajitha","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.lfs.2020.118907_bb0100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.biochem.71.102301.093055","article-title":"Mammalian ABC transporters in health and disease","volume":"71","author":"Borst","year":"2002","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.lfs.2020.118907_bb0105","first-page":"2532","article-title":"Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2","volume":"59","author":"Hooijberg","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0110","first-page":"473","article-title":"Methotrexate in rheumatoid arthritis","volume":"58","author":"Swierkot","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.lfs.2020.118907_bb0115","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cpdd.109","article-title":"The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis","volume":"3","author":"Liu","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.lfs.2020.118907_bb0120","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.2147\/IJN.S167443","article-title":"Effects of PEG surface density and chain length on the pharmacokinetics and biodistribution of methotrexate-loaded chitosan nanoparticles","volume":"13","author":"Ait Bachir","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2020.118907_bb0125","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2020.118907_bb0130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1172\/JCI111761","article-title":"Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow","volume":"75","author":"Koizumi","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2020.118907_bb0135","first-page":"313","article-title":"Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis","volume":"17","author":"Angelis-Stoforidis","year":"1999","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/ph5080802","article-title":"Involvement of multiple transporters-mediated transports in mizoribine and methotrexate pharmacokinetics","volume":"5","author":"Murakami","year":"2012","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.lfs.2020.118907_bb0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1172\/JCI110624","article-title":"Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells","volume":"70","author":"Jolivet","year":"1982","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2020.118907_bb0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/bj2360193","article-title":"Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5\u2032-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide","volume":"236","author":"Baggott","year":"1986","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2020.118907_bb0155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2125.1993.tb04158.x","article-title":"The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis","volume":"35","author":"Seideman","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00003088-200342020-00003","article-title":"Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases","volume":"42","author":"Grim","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.lfs.2020.118907_bb0165","first-page":"745","article-title":"Methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"16","author":"Sinnett","year":"1989","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2125.1998.t01-1-00790.x","article-title":"The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis","volume":"46","author":"Godfrey","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ptr.5032","article-title":"Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine","volume":"28","author":"Zhang","year":"2014","journal-title":"Phytother. Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0180","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000356817","article-title":"Life-threatening gastrointestinal mucosal necrosis during methotrexate treatment for rheumatoid arthritis","volume":"7","author":"Tsukada","year":"2013","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.lfs.2020.118907_bb0185","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2020.118907_bb0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.lfs.2020.118907_bb0195","first-page":"63","article-title":"Rheumatoid arthritis and B-cell chronic lymphocytic leukemia","volume":"20","author":"Voulgari","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0200","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2020.118907_bb0205","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/00498250701867889","article-title":"Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition","volume":"38","author":"Zhou","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.lfs.2020.118907_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1101\/gr.203201","article-title":"Systematic identification of novel protein domain families associated with nuclear functions","volume":"12","author":"Doerks","year":"2002","journal-title":"Genome Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22060871","article-title":"Natural products as alternative choices for P-glycoprotein (P-gp) inhibition","volume":"22","author":"Dewanjee","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2020.118907_bb0220","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/dmd.30.7.838","article-title":"Tissue distribution and chemical induction of multiple drug resistance genes in rats","volume":"30","author":"Brady","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.lfs.2020.118907_bb0225","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5493\/wjem.v5.i4.225","article-title":"Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis","volume":"5","author":"Tsujimura","year":"2015","journal-title":"World J. Exp. Med."},{"key":"10.1016\/j.lfs.2020.118907_bb0230","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0235","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/A:1012823120935","article-title":"Complete characterization of the human ABC gene family","volume":"33","author":"Dean","year":"2001","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.lfs.2020.118907_bb0240","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/s10165-009-0247-0","article-title":"Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis","volume":"20","author":"Tsujimura","year":"2010","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0245","article-title":"Overexpression of P-glycoprotein on fibroblast-like synoviocytes in refractory rheumatoid arthritis patients: a potential mechanism for multidrug resistance in rheumatoid arthritis treatment","volume":"15","author":"Liu","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0250","doi-asserted-by":"crossref","first-page":"3619320","DOI":"10.1155\/2018\/3619320","article-title":"Methotrexate combined with 4-hydroperoxycyclophosphamide downregulates multidrug-resistance P-glycoprotein expression induced by methotrexate in rheumatoid arthritis fibroblast-like synoviocytes via the JAK2\/STAT3 pathway","volume":"2018","author":"Qin","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.lfs.2020.118907_bb0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.taap.2016.06.030","article-title":"P-gp, MRP2 and OAT1\/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate","volume":"306","author":"Jia","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/pgs.15.150","article-title":"Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients","volume":"17","author":"Moya","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.lfs.2020.118907_bb0265","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2133\/dmpk.DMPK-11-RG-066","article-title":"Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis","volume":"27","author":"Kato","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.lfs.2020.118907_bb0270","first-page":"546","article-title":"ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients","volume":"24","author":"Takatori","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0275","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/omi.2011.0142","article-title":"Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis","volume":"16","author":"Plaza-Plaza","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.lfs.2020.118907_bb0280","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/pgs.09.139","article-title":"Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis","volume":"11","author":"Kooloos","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.lfs.2020.118907_bb0285","first-page":"3458","article-title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues","volume":"61","author":"Maliepaard","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0290","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.ki.5002645","article-title":"The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane","volume":"73","author":"Huls","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2020.118907_bb0295","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.drup.2006.09.001","article-title":"The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis","volume":"9","author":"Assaraf","year":"2006","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.lfs.2020.118907_bb0300","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/ard.2002.005249","article-title":"Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha","volume":"63","author":"van der Heijden","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118907_bb0305","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/art.24354","article-title":"Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide","volume":"60","author":"van der Heijden","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2020.118907_bb0310","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.pharmtox.46.120604.141238","article-title":"Role of ABCG2\/BCRP in biology and medicine","volume":"46","author":"Krishnamurthy","year":"2006","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2020.118907_bb0315","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10555-007-9042-6","article-title":"ABCG2: determining its relevance in clinical drug resistance","volume":"26","author":"Robey","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.lfs.2020.118907_bb0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejps.2011.03.006","article-title":"In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate","volume":"43","author":"Elsby","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2020.118907_bb0325","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2020.118907_bb0330","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/toxsci\/kfu162","article-title":"SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients","volume":"142","author":"Lima","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.lfs.2020.118907_bb0335","first-page":"205","article-title":"Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study","volume":"11","author":"Baghdadi","year":"2018","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/j.lfs.2020.118907_bb0340","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.V881213","article-title":"Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules","volume":"8","author":"Schaub","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2020.118907_bb0345","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/tpj.2016.36","article-title":"Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis","volume":"17","author":"Jenko","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.lfs.2020.118907_bb0350","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.4049\/jimmunol.176.9.5191","article-title":"Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation","volume":"176","author":"van de Ven","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2020.118907_bb0355","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ard.2003.017566","article-title":"Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors","volume":"64","author":"Radstake","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118907_bb0360","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/art.22748","article-title":"Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis","volume":"56","author":"Timmer","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2020.118907_bb0365","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.106.110379","article-title":"Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2\/ABCC2- and MRP4\/ABCC4-mediated methotrexate transport","volume":"320","author":"El-Sheikh","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2020.118907_bb0370","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/jpet.106.101774","article-title":"Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice","volume":"318","author":"Vlaming","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2020.118907_bb0375","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/sj.tpj.6500438","article-title":"Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis","volume":"7","author":"Drozdzik","year":"2007","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.lfs.2020.118907_bb0380","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13000-015-0447-1","article-title":"MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients","volume":"10","author":"Micsik","year":"2015","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.lfs.2020.118907_bb0385","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2020.118907_bb0390","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/ard.2003.014985","article-title":"Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis","volume":"64","author":"Wolf","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118907_bb0395","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/ard.2005.049189","article-title":"Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug","volume":"65","author":"Hider","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118907_bb0400","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/03009740310004333","article-title":"Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview","volume":"32","author":"Jansen","year":"2003","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0405","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/mol.117.110593","article-title":"Leflunomide increases hepatic exposure to methotrexate and its metabolite by differentially regulating multidrug resistance-associated protein Mrp2\/3\/4 transporters via peroxisome proliferator-activated receptor \u03b1 activation","volume":"93","author":"Wang","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0410","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00439-019-02081-x","article-title":"The genetic landscape of the human solute carrier (SLC) transporter superfamily","volume":"138","author":"Schaller","year":"2019","journal-title":"Hum. Genet."},{"key":"10.1016\/j.lfs.2020.118907_bb0415","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","article-title":"Organic anion transporting polypeptides of the OATP\/ SLC21 family: phylogenetic classification as OATP\/ SLCO superfamily, new nomenclature and molecular\/functional properties","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.lfs.2020.118907_bb0420","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2020.118907_bb0425","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00232-005-7004-x","article-title":"Organic anion transporting polypeptides of the OATP\/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode","volume":"208","author":"Meier-Abt","year":"2005","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.lfs.2020.118907_bb0430","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.addr.2016.06.004","article-title":"Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition","volume":"116","author":"Zhou","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2020.118907_bb0435","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0440","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The SLCO (former SLC21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.lfs.2020.118907_bb0445","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/acs.molpharmaceut.5b00453","article-title":"Preclinical mouse models to study human OATP1B1- and OATP1B3-mediated drug-drug interactions in vivo","volume":"12","author":"Durmus","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2020.118907_bb0450","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2020.118907_bb0455","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/1389200220666190701094756","article-title":"Influence of the OATP polymorphism on the population pharmacokinetics of methotrexate in Chinese patients","volume":"20","author":"Wang","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.lfs.2020.118907_bb0460","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FPC.0b013e32835c3b24","article-title":"Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia","volume":"23","author":"Lopez-Lopez","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.lfs.2020.118907_bb0465","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by Organic Anion Transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2020.118907_bb0470","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11095-007-9407-0","article-title":"Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates","volume":"25","author":"VanWert","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2020.118907_bb0475","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2133\/dmpk.19.369","article-title":"Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3","volume":"19","author":"Uwai","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.lfs.2020.118907_bb0480","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/toxins2082055","article-title":"Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity","volume":"2","author":"Hagos","year":"2010","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.lfs.2020.118907_bb0485","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-pharmtox-011112-140317","article-title":"Renal transporters in drug development","volume":"53","author":"Morrissey","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2020.118907_bb0490","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/00042737-200112000-00001","article-title":"Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs","volume":"13","author":"Naesdal","year":"2001","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0495","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0091270005280100","article-title":"Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis","volume":"45","author":"Vakily","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0500","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.biopha.2018.04.122","article-title":"Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro","volume":"103","author":"Liu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2020.118907_bb0505","first-page":"1469","article-title":"Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis","volume":"17","author":"Dupuis","year":"1990","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0510","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/0091270009338939","article-title":"Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"49","author":"Schwartz","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0515","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1432-1327.2000.01049.x","article-title":"Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental leukemia cells","volume":"267","author":"Drori","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.lfs.2020.118907_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.10195","article-title":"Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida","volume":"108","author":"Shaw","year":"2002","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.lfs.2020.118907_bb0525","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.intimp.2016.05.012","article-title":"The association between reduced folate carrier-1 gene 80G\/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: a meta-analysis","volume":"38","author":"Li","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0530","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V89.3.1013","article-title":"Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression","volume":"89","author":"Gorlick","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2020.118907_bb0535","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0006-2952(01)00535-4","article-title":"Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells","volume":"61","author":"Ding","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0540","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/bj20020801","article-title":"Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines","volume":"367","author":"Rothem","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2020.118907_bb0545","doi-asserted-by":"crossref","first-page":"10388","DOI":"10.1074\/jbc.274.15.10388","article-title":"Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier","volume":"274","author":"Wong","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2020.118907_bb0550","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/rheumatology\/ken073","article-title":"Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells","volume":"47","author":"Baslund","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lfs.2020.118907_bb0555","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/mgme.2000.3034","article-title":"A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia","volume":"70","author":"Chango","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.lfs.2020.118907_bb0560","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00008571-200411000-00004","article-title":"Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis","volume":"14","author":"Dervieux","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.lfs.2020.118907_bb0565","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/pgs.13.244","article-title":"SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients","volume":"15","author":"Lima","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.lfs.2020.118907_bb0570","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2011.e3","article-title":"Subcellular localization and distribution of the reduced folate carrier in normal rat tissues","volume":"55","author":"Hinken","year":"2011","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.lfs.2020.118907_bb0575","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1517\/14622416.3.3.299","article-title":"Pharmacogenetics and folate metabolism -- a promising direction","volume":"3","author":"Ulrich","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.lfs.2020.118907_bb0580","doi-asserted-by":"crossref","first-page":"13558","DOI":"10.1038\/srep13558","article-title":"Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3\/Nf-\u03bab pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.118907_bb0585","doi-asserted-by":"crossref","first-page":"31185","DOI":"10.1074\/jbc.M110.107805","article-title":"Regulation of MRP2\/ABCC2 and BSEP\/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}","volume":"285","author":"Diao","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2020.118907_bb0590","doi-asserted-by":"crossref","first-page":"G831","DOI":"10.1152\/ajpgi.00307.2004","article-title":"Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver","volume":"289","author":"Geier","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.lfs.2020.118907_bb0595","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.108.023630","article-title":"Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6","volume":"37","author":"Le Vee","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.lfs.2020.118907_bb0600","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/jps.20072","article-title":"Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells","volume":"93","author":"Belliard","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2020.118907_bb0605","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4062\/biomolther.2012.20.3.293","article-title":"The changes of P-glycoprotein activity by interferon-\u03b3 and tumor necrosis factor-\u03b1 in primary and immortalized human brain microvascular endothelial cells","volume":"20","author":"Lee","year":"2012","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.lfs.2020.118907_bb0610","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1053\/jhep.2003.50317","article-title":"Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis","volume":"38","author":"Geier","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.lfs.2020.118907_bb0615","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/mol.106.029512","article-title":"Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier","volume":"71","author":"Bauer","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0620","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/SHK.0b013e318150762b","article-title":"IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters","volume":"29","author":"Andrejko","year":"2008","journal-title":"Shock"},{"key":"10.1016\/j.lfs.2020.118907_bb0625","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2005070727","article-title":"Prostaglandin E2 inhibits its own renal transport by downregulation of organic anion transporters rOAT1 and rOAT3","volume":"17","author":"Sauvant","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2020.118907_bb0630","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejps.2014.05.023","article-title":"Upregulation of COX-2 in the lung cancer promotes overexpression of multidrug resistance protein 4 (MRP4) via PGE2-dependent pathway","volume":"62","author":"Maeng","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2020.118907_bb0635","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1208\/s12248-019-0303-4","article-title":"Activation of protein kinase A stimulates SUMOylation, expression, and transport activity of organic anion transporter 3","volume":"21","author":"Wang","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.lfs.2020.118907_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18040764","article-title":"Protein kinases C-mediated regulations of drug transporter activity, localization and expression","volume":"18","author":"Mayati","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2020.118907_bb0645","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.lfs.2020.118907_bb0650","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00228-008-0521-7","article-title":"Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism","volume":"64","author":"Bohanec Grabar","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0655","first-page":"572","article-title":"Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis","volume":"35","author":"Ranganathan","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118907_bb0660","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/FPC.0b013e3283398a71","article-title":"Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate","volume":"20","author":"Stamp","year":"2010","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.lfs.2020.118907_bb0665","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/aje\/kws330","article-title":"Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study","volume":"177","author":"Zhang","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.lfs.2020.118907_bb0670","doi-asserted-by":"crossref","first-page":"G156","DOI":"10.1152\/ajpgi.2000.278.1.G156","article-title":"A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane","volume":"278","author":"K\u00f6nig","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.lfs.2020.118907_bb0675","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":"Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects","volume":"27","author":"Trevi\u00f1o","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.118907_bb0680","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1006\/bbrc.2001.4774","article-title":"Isolation of a family of organic anion transporters from human liver and kidney","volume":"283","author":"Sun","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2020.118907_bb0685","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1124\/jpet.105.084301","article-title":"Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6)","volume":"314","author":"Bleasby","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2020.118907_bb0690","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2006.02655.x","article-title":"Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters","volume":"62","author":"Vormfelde","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118907_bb0695","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2217\/pgs.12.150","article-title":"Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients","volume":"13","author":"Bohanec Grabar","year":"2012","journal-title":"Pharmacogenomics"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520316660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520316660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:40:42Z","timestamp":1758400842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520316660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":139,"alternative-id":["S0024320520316660"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118907","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of drug transporters on the efficacy of methotrexate in the treatment of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118907"}}